Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Treatment Convergence: Management of Schizophrenia and Bipolar Disorder with Atypical Antipsychotics

Premiere Date: Thursday, November 16, 2006
Live Audioconference Series (10 sessions): November - December, 2006

This activity offers CE credit for:

1. Physicians (ACCME/AMA PRA Category 1)
2. Nurses (CNE)
3. Pharmacists (ACPE)
4. Psychologists (APA)
5. Social Workers (NASW)
6. Certified Case Managers (CCMC)

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Saturday, December 15, 2007
Note: Credit Is No Longer Available

Faculty

John M. Kane, MD  Senior Vice President, Behavioral Health Services, Northwell Health New Hyde Park, NY Chairman, Department of Psychiatry, Zucker Hillside Hospital Glen Oaks, NY Professor and Chairman of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, NY

Paul E. Keck, Jr., MD  President-CEO, Lindner Center of HOPE Professor of Psychiatry & Behavior Neuroscience University of Cincinnati College of Medicine Cincinnati, OH

Statement of Need

Schizophrenia is a chronic, debilitating psychiatric disorder that significantly impacts social, occupational, and cognitive functioning. Bipolar disorder (BPD) also affects social and occupational functioning, and can cause significant morbidity and mortality. The effective management of schizophrenia and BPD is frequently complicated by real-world challenges such as adherence. Treatment adherence can be determined in part by medication efficacy and side effects.(1) Atypical antipsychotics are the recommended first-line therapy for the treatment of schizophrenia.(2) Recent clinical evidence indicates that combining atypical antipsychotics with mood stabilizers may provide more effective management of bipolar mania than a mood stabilizer alone.(3) Psychotherapeutic interventions in combination with pharmacotherapy also play an integral role in the treatment of schizophrenia and bipolar disorder by markedly improving adherence to medication.(4,5) While atypical antipsychotics are useful tools in the arsenal to manage schizophrenia and BPD, they are not without limitations. As a class, atypical agents may produce weight gain as well as glucose and lipid dysregulation, all of which can decrease treatment adherence. In this evidence-based CME Outfitters/psychCME activity, the experts will discuss the convergence of pharmacologic approaches to schizophrenia and bipolar disorder,(6) and propose strategies for improving outcomes in the treatment of these challenging patients.

---

1. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651.
2. Practice guideline for the treatment of schizophrenia, 2nd edition. American Psychiatric Association, Feb 2004.
3. Keck PE, Jr., Marcus R, Tourkodimitris S, et al. Aripiprazole Study Group. A placebo-controlled double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658.
4. Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv 2004;55:264-269.
5. Turkington D, Dudley R, Warman DM, Beck AT. Cognitive-behavioral therapy for schizophrenia: a review. J Psychiatr Pract 2004;10:5-16.
6. Citrome L, Goldberg JG, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 2005;13:28-42.

Activity Goal

To provide clinicians with current evidence-based educational information to effectively implement appropriate treatment strategies for schizophrenia and bipolar disorder.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Compare and contrast the use of atypical antipsychotics in patients with schizophrenia and bipolar disorder.
• Identify factors that contribute to discontinuation of medication in patients with schizophrenia and bipolar disorder.
• Develop treatment strategies that utilize pharmacological and nonpharmacologic approaches to achieve optimal outcomes in patients with schizophrenia and bipolar disorder.

Target Audience

Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
This Educational Activity is presented by CME Outfitters, LLC, which has been approved as a provider of continuing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

It has been assigned code 5UYSJZ-PRV-04104. 1.0 contact hour (Pharmacology)

CEP Credit (Psychologists):
CME Outfitters is approved by the American Psychological Association to sponsor continuing education for psychologists. CME Outfitters maintains responsibility for this program and its content. (1.0 CE credits)

NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing education contact hour.

CCMC Credit (Certified Case Managers):
This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-999-06-020-L01 (live interactive session) 376-999-06-020-H01 (recorded activities)

To receive credit, participants must review all activity materials in their entirety, score 70% or above on a post-test, and fully complete and return both the credit request form and activity evaluation. A certificate or statement of credit will be mailed within 4-6 weeks to all who successfully complete these requirements.

Disclosure Declaration

All faculty participating in CME Outfitters continuing education activities are required to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's Standards for Commercial Support, and other accrediting and regulatory bodies. Full disclosure of faculty relationships will be made on this website and within the activity course materials prior to the premiere date of this activity.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).